Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 46 articles:
HTML format



Single Articles


    November 2021
  1. JAVELLANA M, Eckert MA, Heide J, Zawieracz K, et al
    Neoadjuvant chemotherapy induces genomic and transcriptomic changes in ovarian cancer.
    Cancer Res. 2021 Nov 4. pii: 0008-5472.CAN-21-1467.
    PubMed     Abstract available


    October 2021
  2. RAY U, Jung DB, Jin L, Xiao Y, et al
    Targeting LRRC15 inhibits metastatic dissemination of ovarian cancer.
    Cancer Res. 2021 Oct 15. pii: 0008-5472.CAN-21-0622.
    PubMed     Abstract available


    September 2021
  3. LECKER LS, Berlato C, Maniati E, Delaine-Smith R, et al
    TGFBI production by macrophages contributes to an immunosuppressive microenvironment in ovarian cancer.
    Cancer Res. 2021 Sep 24. pii: 0008-5472.CAN-21-0536.
    PubMed     Abstract available


    August 2021
  4. MCDONALD JI, Diab N, Arthofer E, Hadley M, et al
    Epigenetic therapies in ovarian cancer alter repetitive element expression in a TP53-dependent manner.
    Cancer Res. 2021 Aug 25. pii: 0008-5472.CAN-20-4243.
    PubMed     Abstract available


  5. GEETHADEVI A, Nair A, Parashar D, Ku Z, et al
    Oncostatin M Receptor-targeted antibodies suppress STAT3 signaling and inhibit ovarian cancer growth.
    Cancer Res. 2021 Aug 11. pii: 0008-5472.CAN-21-0483.
    PubMed     Abstract available


    June 2021
  6. PATEL M, Wang Y, Bartom ET, Dhir R, et al
    The ratio of toxic-to-nontoxic microRNAs predicts platinum sensitivity in ovarian cancer.
    Cancer Res. 2021 Jun 15. pii: 0008-5472.CAN-21-0953.
    PubMed     Abstract available


    May 2021
  7. FARKKILA A, Rodriguez A, Oikkonen J, Gulhan DC, et al
    Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.
    Cancer Res. 2021;81:2774-2787.
    PubMed     Abstract available


    April 2021
  8. SCHOUTROP E, El-Serafi I, Poiret T, Zhao Y, et al
    Mesothelin-specific CAR T cells target ovarian cancer.
    Cancer Res. 2021 Apr 1. pii: 0008-5472.CAN-20-2701.
    PubMed     Abstract available


    February 2021
  9. BELUR NAGARAJ A, Knarr M, Sekhar S, Connor RS, et al
    The miR-181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer.
    Cancer Res. 2021 Feb 11. pii: 0008-5472.CAN-20-2041.
    PubMed     Abstract available


    January 2021
  10. SHRESTHA R, Llaurado Fernandez M, Dawson A, Hoenisch J, et al
    Multiomics characterization of low-grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability.
    Cancer Res. 2021 Jan 13. pii: 0008-5472.CAN-20-2222.
    PubMed     Abstract available


    December 2020
  11. KARLSSON T, Johansson T, Hoglund J, Ek WE, et al
    Time-dependent effects of oral contraceptive use on breast, ovarian and endometrial cancers.
    Cancer Res. 2020 Dec 17. pii: 0008-5472.CAN-20-2476.
    PubMed     Abstract available


    November 2020
  12. DRERUP JM, Deng Y, Pandeswara SL, Padron AS, et al
    CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
    Cancer Res. 2020;80:5063-5075.
    PubMed     Abstract available


  13. WANG Y, Zhao G, Condello S, Huang H, et al
    Frizzled-7 Identifies Platinum Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
    Cancer Res. 2020 Nov 10. pii: 0008-5472.CAN-20-1488.
    PubMed     Abstract available


  14. WAN C, Keany MP, Dong H, Al-Alem LF, et al
    Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high grade serous ovarian cancer.
    Cancer Res. 2020 Nov 6. pii: 0008-5472.CAN-20-1674.
    PubMed     Abstract available


    October 2020
  15. PARASHAR D, Nair B, Geethadevi A, George J, et al
    Peritoneal Spread of Ovarian Cancer harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
    Cancer Res. 2020 Oct 21. pii: 0008-5472.CAN-19-3717.
    PubMed     Abstract available


  16. SHEN YA, Hong J, Asaka R, Asaka S, et al
    Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
    Cancer Res. 2020;80:4514-4526.
    PubMed     Abstract available


    September 2020
  17. TAMURA N, Shaikh N, Muliaditan D, Soliman TN, et al
    Specific mechanisms of chromosomal instability indicate therapeutic sensitivities in high-grade serous ovarian carcinoma.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-19-0852.
    PubMed     Abstract available


  18. HUANG TT, Brill E, Nair JR, Zhang X, et al
    Targeting the PI3K/mTOR pathway augments CHK1 inhibitor-induced replication stress and antitumor activity in high-grade serous ovarian cance.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-20-1439.
    PubMed     Abstract available


  19. AZAR WJ, Christie EL, Mitchell C, Liu DS, et al
    Non-canonical IL-6 signaling-mediated activation of YAP regulates cell migration and invasion in ovarian clear cell cancer.
    Cancer Res. 2020 Sep 11. pii: 0008-5472.CAN-19-3044.
    PubMed     Abstract available


  20. CARLES A, Trigo-Gonzalez G, Cao Q, Cheng SG, et al
    The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity.
    Cancer Res. 2020;80:3480-3491.
    PubMed     Abstract available


  21. WEIS-BANKE SE, Lerdrup M, Kleine-Kohlbrecher D, Mohammad F, et al
    Mutant FOXL2(C134W) Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors.
    Cancer Res. 2020;80:3466-3479.
    PubMed     Abstract available


  22. TUBEUF H, Caputo SM, Sullivan T, Rondeaux J, et al
    Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System.
    Cancer Res. 2020;80:3593-3605.
    PubMed     Abstract available


    August 2020
  23. ZONG X, Wang W, Ozes A, Fang F, et al
    EZH2-mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
    Cancer Res. 2020 Aug 19. pii: 0008-5472.CAN-20-0458.
    PubMed     Abstract available


  24. PALMER AC, Plana D, Gao H, Korn JM, et al
    A proof of concept for biomarker-guided targeted therapy against ovarian cancer based on patient-derived tumor xenografts.
    Cancer Res. 2020 Aug 3. pii: 0008-5472.CAN-19-3850.
    PubMed     Abstract available


  25. GEISTLINGER L, Oh S, Ramos M, Schiffer L, et al
    Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma.
    Cancer Res. 2020 Aug 3. pii: 0008-5472.CAN-20-0521.
    PubMed     Abstract available


    July 2020
  26. ASARE-WEREHENE M, Communal L, Carmona E, Han Y, et al
    Plasma gelsolin inhibits CD8+ T cell function and regulates glutathione production to confer chemoresistance in ovarian cancer.
    Cancer Res. 2020 Jul 8. pii: 0008-5472.CAN-20-0788.
    PubMed     Abstract available


    June 2020
  27. HUANG H, Wang Y, Kandpal M, Zhao G, et al
    FTO-Dependent N6-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling.
    Cancer Res. 2020 Jun 30. pii: 0008-5472.CAN-19-4044.
    PubMed     Abstract available


    May 2020
  28. MATEI D, Nephew KP
    Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes.
    Cancer Res. 2020 May 7. pii: 0008-5472.CAN-19-3837.
    PubMed     Abstract available


    April 2020
  29. MEULEMANS L, Mesman RLS, Caputo SM, Krieger S, et al
    Skipping Nonsense to Maintain Function: The Paradigm of BRCA2 Exon 12.
    Cancer Res. 2020;80:1374-1386.
    PubMed     Abstract available


    February 2020
  30. MCCOOL KW, Freeman ZT, Zhai Y, Wu R, et al
    Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
    Cancer Res. 2020;80:877-889.
    PubMed     Abstract available


  31. MUKHERJEE A, Chiang CY, Daifotis HA, Nieman KM, et al
    Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance.
    Cancer Res. 2020 Feb 13. pii: 0008-5472.CAN-19-1999.
    PubMed     Abstract available


    January 2020
  32. ZELEZNIK OA, Eliassen AH, Kraft P, Poole EM, et al
    A prospective analysis of circulating plasma metabolites associated with ovarian cancer risk.
    Cancer Res. 2020 Jan 22. pii: 0008-5472.CAN-19-2567.
    PubMed     Abstract available


  33. TRABERT B, Tworoger SS, O'Brien KM, Townsend MK, et al
    The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the Ovarian Cancer Cohort Consortium (OC3).
    Cancer Res. 2020 Jan 13. pii: 0008-5472.CAN-19-2850.
    PubMed     Abstract available


  34. ASEM M, Young AM, Oyama C, Claure De La Zerda AG, et al
    Host Wnt5a Potentiates Microenvironmental Regulation of Ovarian Cancer Metastasis.
    Cancer Res. 2020 Jan 13. pii: 0008-5472.CAN-19-1601.
    PubMed     Abstract available


    December 2019
  35. NACARELLI T, Fukumoto T, Zundell JA, Fatkhutdinov N, et al
    NAMPT inhibition suppresses cancer stem-like cells associated with therapy-induced senescence in ovarian cancer.
    Cancer Res. 2019 Dec 19. pii: 0008-5472.CAN-19-2830.
    PubMed     Abstract available


  36. MOYER CL, Ivanovich J, Gillespie JL, Doberstein R, et al
    Rare BRIP1 missense alleles confer risk for ovarian and breast cancer.
    Cancer Res. 2019 Dec 10. pii: 0008-5472.CAN-19-1991.
    PubMed     Abstract available


    November 2019
  37. LI C, Course MM, McNeish IA, Drescher CW, et al
    Prophylactic in vivo hematopoietic stem cell gene therapy with an immune checkpoint inhibitor reverses tumor growth in syngeneic mouse tumor models.
    Cancer Res. 2019 Nov 14. pii: 0008-5472.CAN-19-1044.
    PubMed     Abstract available


    October 2019
  38. KANAKKANTHARA A, Kurmi K, Ekstrom TL, Hou X, et al
    BRCA1 Deficiency Upregulates NNMT Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
    Cancer Res. 2019 Oct 16. pii: 0008-5472.CAN-19-1405.
    PubMed     Abstract available


  39. CARBONE M, Melino G
    Stearoyl CoA Desaturase Regulates Ferroptosis in Ovarian Cancer Offering New Therapeutic Perspectives.
    Cancer Res. 2019;79:5149-5150.
    PubMed     Abstract available


    September 2019
  40. CHUI MH, Doodnauth SA, Erdmann N, Tiedemann RE, et al
    Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma.
    Cancer Res. 2019 Sep 17. pii: 0008-5472.CAN-18-3029.
    PubMed     Abstract available


    June 2019
  41. FUKUMOTO T, Zhu H, Nacarelli T, Karakashev S, et al
    N(6)-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance.
    Cancer Res. 2019;79:2812-2820.
    PubMed     Abstract available


    April 2019
  42. RAMAMOORTHY P, Thomas SM, Kaushik G, Subramaniam D, et al
    Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response.
    Cancer Res. 2019;79:1681-1695.
    PubMed     Abstract available


    March 2019
  43. PRICE C, Gill S, Ho ZV, Davidson SM, et al
    Genome-wide interrogation of human cancers identifies EGLN1 dependency in clear cell ovarian cancers.
    Cancer Res. 2019 Mar 21. pii: 0008-5472.CAN-18-2674.
    PubMed     Abstract available


    February 2019
  44. MCCORMICK PN, Greenwood HE, Glaser M, Maddocks ODK, et al
    Assessment of Tumor Redox Status through (S)-4-(3-[(18)F]fluoropropyl)-L-Glutamic Acid PET Imaging of System xc (-) Activity.
    Cancer Res. 2019;79:853-863.
    PubMed     Abstract available


    January 2019
  45. DYER A, Schoeps B, Frost S, Jakeman P, et al
    Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.
    Cancer Res. 2019;79:331-345.
    PubMed     Abstract available


  46. SHEN J, Zhao W, Ju Z, Wang L, et al
    PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    Cancer Res. 2019;79:311-319.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: